Phase 2 Pulmonary Hypertension Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older, of any gender
• People who have been diagnosed with intrahepatic cholangiocarcinoma (a type of bile duct cancer inside the liver) that can be surgically removed, and who meet at least one of the following: a single tumour larger than 5cm; a single tumour that has grown into nearby blood vessels, or up to 3 tumours total; a tumour that has grown through the outer lining of the liver or into surrounding organs; or suspected spread to certain nearby lymph nodes (in zones 8, 12, or 13)
• People who have not yet received any systemic (whole-body) treatment for this cancer
• People with a good general level of physical functioning, rated 0 or 1 on a standard medical scale (ECOG score), meaning they are fully active or have only minor limitations in daily activity
• People whose major organs — including heart, lungs, liver, kidneys, bone marrow, and immune system — are functioning adequately, with no serious abnormalities
• Women of childbearing age for whom a pregnancy test (blood or urine) taken within 14 days before joining comes back negative, and who agree to use effective contraception during the trial and for 8 weeks after the last dose of study treatment
• Men who have had a surgical procedure to prevent fathering children, or who agree to use effective contraception during the trial and for 8 weeks after the last dose of study treatment
• People who are willing to sign a consent form and voluntarily participate
• People who are expected to attend all required follow-up visits and comply with the trial schedule

Who may not be able to join:

• People who have previously received certain immune-based treatments, including PD-1, PD-L1, PD-L2, or CTLA-4 inhibitors, or other drugs that affect specific immune system receptors
• People who have taken any other experimental (research) drug within 4 weeks before joining
• People who have an active autoimmune disease or a history of one, such as autoimmune lung inflammation, eye inflammation, bowel inflammation, liver inflammation, or thyroid conditions — among others (confirm with trial site for the full list)
• People who have a weakened immune system due to an inherited condition or a disease such as HIV infection
• People with serious, uncontrolled heart conditions, such as moderate-to-severe heart failure, unstable chest pain (angina), a heart attack within the past year, or significant abnormal heart rhythms that require medical treatment
• People who had a serious infection requiring intravenous antibiotics, antifungal, or antiviral medicines within 4 weeks before starting the trial, or who had an unexplained fever above 38.5°C around the time of screening
• People who have previously received a transplanted organ or bone marrow/stem cells from another person
• People who have received a live vaccine within 4 weeks before starting the trial, or who plan to receive one during the trial period
• People who have had another type of cancer in the past 5 years — except for certain cancers considered fully cured, such as a specific type of skin cancer (basal cell carcinoma), early-stage cervical cancer, or ovarian cancer
• People who are known to be allergic to any of the study drugs
• Women who are pregnant or breastfeeding, or people who are able to have children but are unwilling to use effective contraception
• People with a psychiatric condition that is not under control
• People with central nervous system (brain or spinal cord) spread of cancer, seriously abnormal lab results, or other circumstances the trial team considers unsuitable for participation (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.